Company news: Cancer Research UK, the Generic Pharmaceutical Association

Share this article:
A genetic study of breast cancer has found ten distinct types of the disease and ferreted out “a slew” of previously unknown genetic factors that influence the cancer's aggressiveness. Researchers on the METABRIC study, published in the journal Nature, looked at 2,000 breast tumors taken from women diagnosed between five and ten years ago and found ten types varying widely in aggressiveness and responsiveness to extant therapies. The findings, wrote Cancer Research UK chief Dr. Harpal Kumar, “confirm that our existing ‘breast cancer map' is outdated—there should be 10 ‘countries,' not four ‘continents' – and this is now territory we need to urgently explore.” Dr. Kumar, writing in The Guardian, said “the study identified a slew of new cancer genes, which will make excellent targets for a new generation of Herceptin-like drugs. We hope that, one day, drugs will exist for all these subgroups, so no woman will ever have to be told she has the ‘wrong' type of breast cancer.” The current classification scheme, which groups breast cancer into four categories based on whether tumors are estrogen-positive or HER2 gene-positive and directs treatment accordingly (hormone therapies like Tamoxifen for the former, Herceptin for the latter), is too “simplistic,” wrote Dr. Kumar. “One of the newly discovered types consisted of women with apparently aggressive cancers who actually did very well,” he wrote. “Closer inspection showed that these women were rescued by their own immune systems. We urgently need to know how.” The study was sponsored by Cancer Research UK.

The Generic Pharmaceutical Association tapped IMS Health to serve as “independent third party” in its Accelerated Recovery Initiative, meant to speed the resolution of drug shortages. IMS, said GPhA, “will play a crucial role in assisting the FDA with a more accurate, timely and comprehensive view of current and potential drug shortage situations, and in establishing practices to lessen or eliminate the impact of a current shortage.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.